The 2024 Imperial College Finding That Reframes Diabetic Foot Pain (And Why Most Endocrinologists Haven’t Caught Up Yet)

Our readers at FootHealth.Life keep writing in with the same sentence. “My doctor told me the nerve damage is permanent. There’s nothing I can do.”

Gabapentin was prescribed. The dose was raised twice in a year. Lyrica was tried. Alpha-lipoic acid. B-12 injections. Compression socks the foot was too sensitive to wear. A REVITIVE platform tried for three months. Nothing held. The burning kept arriving at 3 AM. The morning kept beginning the same way.

So we reached out to two specialists who’ve been working on opposite sides of this problem.

Dr. Marcus Webb — a peripheral vascular medicine specialist with 18 years of clinical practice. And a neurology researcher we consulted whose lab studies microvascular dysfunction in diabetic tissue. He asked not to be named while this article was being prepared.

“The standard explanation patients get in the exam room isn’t wrong, exactly,”1 Dr. Webb says. “But it describes the end of a process, not the beginning. And the difference matters enormously for whether the symptoms have to stay.”

“Most patients are being treated for nerve damage,” the researcher adds. “The 2024 data suggests they should be treated for nerve starvation. Those are very different problems with very different answers.”

We asked both specialists the same question: what did the 2024 European Journal of Vascular and Endovascular Surgery study actually find — and why hasn’t it reached patients?

Their answer reframed almost everything we thought we knew about the cause of diabetic foot pain.

3 facts about diabetic foot pain that explain why every prior treatment failed

Both experts started with the science.

Fact #1: The capillaries feeding the foot’s nerves collapse first — before the nerve fibers themselves degrade

“The peripheral nerves in the foot are fed by some of the smallest blood vessels in the body,”2 the researcher explains. “Capillaries thinner than a human hair. Their entire job is to deliver oxygen and glucose to the nerve tissue.”

“In sustained hyperglycemia, these vessels are among the first structures affected. They narrow. The walls thicken. Eventually red blood cells struggle to pass through at all. This happens years before the nerve itself shows measurable degradation.”

That changes the diagnostic picture entirely. The burning, the tingling, the numbness, the electric shocks at 3 AM — these are not the symptoms of nerve death. They are the symptoms of nerve starvation. Of tissue that is still alive, still trying to signal, through a vascular network that has collapsed around it.

Fact #2: Every standard treatment was solving for the wrong layer

“This is the part that almost nobody explains in a 15-minute appointment,” Dr. Webb says.

“Gabapentin and Lyrica operate on the nerve signal directly. They reduce the misfiring. Alpha-lipoic acid targets oxidative stress in the nerve tissue. B-12 supports myelin health. Compression socks create passive external pressure. All of these are downstream of the capillary collapse.”

“None of them rebuild the vessels. None of them recruit the cells that line those vessels. None of them stimulate angiogenesis — the formation of new blood vessel branches. They’re treating the symptom of starvation, not the starvation itself.”

Fact #3: A starved nerve — unlike a dead one — can come back online when supply is restored

“Here’s the part that changes the prognosis,” the researcher says.

“The 2024 finding — replicated by the Imperial College London NMES trial3 — is that the nerve doesn’t die first. It starves first. And starved tissue, the kind that hasn’t crossed into terminal degradation yet, responds when you restore the blood supply.”

The pathway isn’t severed. The cell bodies are still there. The signal is interrupted because the blood carrying oxygen, glucose, and repair materials has been cut off upstream. Reopen the supply line and the tissue, in many cases, begins functioning again.

Score every treatment you’ve ever tried against the three things a starved nerve actually needs

We asked Dr. Webb to walk us through the most common diabetic neuropathy treatments. One by one. Does each one target the nerve signal? The capillary supply feeding the nerve? Or the underlying vessel rebuild?

The pattern was striking.

“None of these are wrong for what they target,” Dr. Webb said when we showed him the matrix. “They’re wrong for the cause. The first column has been covered for thirty years. The second column has been undertreated. The third column — vessel rebuild — almost no patient has ever been offered.”

The three therapies that reopen the supply line — clinicians call it “Hemodynamic Therapy”

“The research on microvascular recovery has been building for two decades,” the researcher says. “Three modalities, delivered in the same session, are what the trial data points to. Not as a guarantee, but as the threshold the literature keeps converging on.”

The informal clinical name is Hemodynamic Therapy. It’s three things, at once:

1. Targeted heat (104–107°F). Dilates the microvascular channels that have narrowed under years of hyperglycemic stress. The vessels that had reduced to a trickle reopen. This is the first step: making space for blood that has been excluded.

2. Rhythmic compression, calibrated to calf-pump frequency. Mechanically mimics the muscle-pump action of walking. In a healthy person, every footstrike pumps blood through the foot’s vascular bed. For the patient whose neuropathy has made walking painful, that pump has been progressively shutting down. The vibration recreates the mechanical signal without requiring weight-bearing on compromised feet.

3. Low-level neuromuscular electrical stimulation (NMES). The core mechanism from the Imperial College trial protocol. It activates VEGFR2 — the receptor on endothelial cells that responds to vascular growth signals — and mobilizes endothelial progenitor cells (EPCs) from bone marrow. These are the cells responsible for building and repairing capillary walls. In the sedentary diabetic patient, EPC mobilization has essentially stopped. The electrical stimulus recreates the signal that walking normally provides.

“Heat alone doesn’t hold it open. Compression alone doesn’t recruit the cells. NMES alone doesn’t make space in the vessels. Three at once is the threshold the trial measured against,” the researcher says.

What Mayo Clinic, Johns Hopkins, and Imperial College have documented — and why this is only now reaching patients

The mechanism isn’t new in the research literature.

Research groups at Mayo Clinic, Johns Hopkins, and the Cleveland Clinic have published extensively on diabetic microvascular dysfunction over the past decade. They’ve documented how sustained hyperglycemia narrows the capillary bed feeding peripheral nerves and how angiogenic stimuli can, in non-terminal tissue, recruit the endothelial machinery that rebuilds those vessels.

The Imperial College London NMES trial (NCT03767478) took that mechanism and tested it directly. Patients with confirmed peripheral arterial disease and measurable nerve conductivity deficits received daily NMES sessions over ten weeks. Nerve conductivity was measured at baseline and at the trial endpoint. In participants who completed the protocol, conductivity was restored to a measurable degree — an outcome the standard pharmacological treatments do not produce.

Until recently, the protocol existed only in clinical settings. Two to three visits a week. Hundreds of dollars per session. The insurance pre-approvals that most diabetic patients never cleared.

“Most of my patients couldn’t do that — financially, logistically, or because the foot that already hurt was the same foot they would have needed to drive with,” Dr. Webb says. “So they settled for the symptom layer. Which is exactly why the underlying mechanism never had a chance to reverse.”

That has started to change.

Over the last 18 months, a small number of companies have commercialized the three-modality combination for daily home use — designed around the same heat / rhythmic compression / NMES parameters that the trial protocols used. One of them agreed to offer FootHealth.Life readers a direct rate, without the typical clinic markup.

What patients who’ve used it are reporting

The takeaway

Both specialists we spoke with landed on the same point.

Diabetic foot pain doesn’t fail to respond because patients haven’t tried hard enough. It fails because the standard protocol treats the symptom layer — nerve signal modulation — while the upstream cause, the capillary collapse, continues unaddressed. Single-target treatments cannot rebuild a vascular bed they were never designed to touch.

“If you’ve been told the damage is permanent, I’d encourage you to look at protocols that address the capillary supply alongside your existing care,” Dr. Webb said at the end of our call. “Not because any single device is a guarantee. But because the 2024 data on starved-versus-damaged nerves is real, and the standard protocol almost never reflects it.”

Whether it’s a clinic NMES program, an at-home device like Soleus, or something else — the category is what matters.

The era of “just manage it” may finally be ending. Not because the medications got better. Because the research finally separated “the nerves are dead” from “the nerves are starved” — and one of those answers leaves the door open.